Skip Nav Destination
Issues
1 May 2000
ISSN 1078-0432
EISSN 1557-3265
Editorial
Editorials
Advances in Brief
A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer1
Joseph Paul Eder; Philip W. Kantoff; Kristin Roper; GuangXian Xu; Glenn J. Bubley; John Boyden; Linda Gritz; Gail Mazzara; William K. Oh; Philip Arlen; Kwong Y. Tsang; Dennis Panicali; Jeffrey Schlom; Donald W. Kufe
Clinical Trials
Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response1
Jared A. Gollob; James W. Mier; Korina Veenstra; David F. McDermott; Daniel Clancy; Marguerite Clancy; Michael B. Atkins
Predicting Cancer Development in Oral Leukoplakia: Ten Years of Translational Research1
J. Jack Lee; Waun Ki Hong; Walter N. Hittelman; Li Mao; Reuben Lotan; Dong M. Shin; Steven E. Benner; Xiao-Chun Xu; Jin S. Lee; Vali M. Papadimitrakopoulou; Clarissa Geyer; Cherie Perez; Jack W. Martin; Adel K. El-Naggar; Scott. M. Lippman
Radioimmunoguided Surgery in Colorectal Cancer Using a Genetically Engineered Anti-CEA Single-Chain Fv Antibody1
Astrid Mayer; Eleni Tsiompanou; Denise O’Malley; Geoff M. Boxer; Jeetendra Bhatia; Aiden A. Flynn; Kerry A. Chester; Brian R. Davidson; Adam A. M. Lewis; Mark C. Winslet; Amar P. Dhillon; Andrew J. W. Hilson; Richard H. J. Begent
Phase I and Pharmacological Study of Weekly Administration of the Polyamine Synthesis Inhibitor SAM 486A (CGP 48 664) in Patients with Solid Tumors
Ferry A. L. M. Eskens; Gudrun A. Greim; Cornelia van Zuylen; I. Wolff; Louis J. Denis; André S. Th. Planting; Frits A. Muskiet; Jantien Wanders; Nicolas C. Barbet; Les Choi; Renaud Capdeville; Jaap Verweij; A-R. Hanauske; Uta Bruntsch; for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group
Molecular Oncology, Markers, Clinical Correlates
Expression of N-Acetylglucosaminyltransferase V in Colorectal Cancer Correlates with Metastasis and Poor Prognosis1
Kohei Murata; Eiji Miyoshi; Masao Kameyama; Osamu Ishikawa; Toshiyuki Kabuto; Yo Sasaki; Masahiro Hiratsuka; Hiroaki Ohigashi; Shingo Ishiguro; Satoru Ito; Hideo Honda; Fuminori Takemura; Naoyuki Taniguchi; Shingi Imaoka
The Cell Cycle Inhibitors p21WAF1 and p27KIP1 Are Associated with Survival in Patients Treated by Salvage Prostatectomy after Radiation Therapy1
Liang Cheng; Ricardo V. Lloyd; Amy L. Weaver; Thomas M. Pisansky; John C. Cheville; Dharamdas M. Ramnani; Bradley C. Leibovich; Michael L. Blute; Horst Zincke; David G. Bostwick
Coexpression of MUC1 Glycoprotein with Multiple Angiogenic Factors in Non-Small Cell Lung Cancer Suggests Coactivation of Angiogenic and Migration Pathways1
Alexandra Giatromanolaki; Michael I. Koukourakis; Efthimios Sivridis; Keneth O’Byrne; Giles Cox; Philip E. Thorpe; Kevin C. Gatter; Adrian L. Harris
Differential Recognition of a BCR/ABL Peptide by Lymphocytes from Normal Donors and Chronic Myeloid Leukemia Patients1
Carla Bertazzoli; Edoardo Marchesi; Lorena Passoni; Rossella Barni; Fernando Ravagnani; Claudia Lombardo; Gian Marco Corneo; Pietro Pioltelli; Enrico Pogliani; Carlo Gambacorti-Passerini
Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms1
Christiane J. Bruns; Matthew T. Harbison; Darren W. Davis; Charles A. Portera; Rachel Tsan; David J. McConkey; Douglas B. Evans; James L. Abbruzzese; Daniel J. Hicklin; Robert Radinsky
Experimental Therapeutics, Preclinical Pharmacology
Taxol and Discodermolide Represent a Synergistic Drug Combination in Human Carcinoma Cell Lines1
Laura A. Martello; Hayley M. McDaid; Donna Lee Regl; Chia-Ping H. Yang; Dongfang Meng; Thomas R. R. Pettus; Michael D. Kaufman; Hirokazu Arimoto; Samuel J. Danishefsky; Amos B. Smith, III; Susan Band Horwitz
Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor1
Fortunato Ciardiello; Rosa Caputo; Roberto Bianco; Vincenzo Damiano; Grazia Pomatico; Sabino De Placido; A. Raffaele Bianco; Giampaolo Tortora
Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors
Pamela A. Pavco; Karyn S. Bouhana; Anna M. Gallegos; Arun Agrawal; Karin S. Blanchard; Susan L. Grimm; Kristi L. Jensen; Lori E. Andrews; Francine E. Wincott; Patrice A. Pitot; Robert J. Tressler; Cynthia Cushman; Mark A. Reynolds; Tom J. Parry
Cancer Biology, Immunology, Cytokines
Corrections
Addendum
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.